Evaluation of Device Settings for Airway Clearance Using The Monarch Airway Clearance System (HFCWO)

Hill-Rom

Status: Unknown

Conditions: Cystic Fibrosis

Treatments: Device: Monarch Airway Clearance System

Study type: Interventional

Funder types: Industry

Identifiers

NCT03645473

CR-RR-2018-002

Details and patient eligibility

About

The study will be an open label laboratory study with all subjects receiving HFCWO with The Monarch® System

Objective:

Assess device settings and to identify frequency/pressure (intensity) combinations that produce high airflow and oscillating volume

Methodology:

Subjects will receive HFCWO using The Monarch® System at multiple frequency / intensity combinations on a single visit day. Frequency / intensity combinations will be evaluated to determine which settings produce highest airflow and highest oscillating volume.

Full description

The study will be an open-label, laboratory study. All enrolled subjects will receive HFCWO therapy with the Monarch® system. The study will be conducted at one (1) site in the US.

The study will evaluate oscillating airflow and oscillating volume induced during therapy with the Monarch® system. Subjects will also rate the comfort of the therapy. Patients with cystic fibrosis (CF) who meet all of the inclusion criteria and none of the exclusion criteria will be enrolled in the study.

Therapy with the Monarch® system will be delivered using multiple frequency/intensity combination settings. The order of settings will be randomized for each study subject. During therapy oscillating flow and volume measurements will be obtained for each frequency/intensity combination. Following each frequency/intensity combination, subjects will respond to a subjective assessment of the comfort of the therapy by rating the comfort on a visual analogue scale (VAS).

Enrollment: 10 estimated patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented diagnosis of CF (by sweat test and/or genetics
• Age > 15 years
• Require regular home airway clearance therapy
• Current user of The Monarch® System with a minimum of 4 weeks experience with the device
• Signed informed consent. If patient is a minor, parents/guardians must give written informed consent and patient must give written assent
• Patient must be on a stable regimen of CF medication

Exclusion criteria

• History of pneumothorax within the past 6 months prior to study visit
• History of hemoptysis requiring embolization within the past 12 months prior to study visit or hemoptysis of > 100 ml within a 24-hour period within the past 30 days
• History of lobectomy
• Recent chest surgery or chest trauma
• Inability to perform The Monarch® System therapy as directed
• Pregnant or lactating female
• Have a pacemaker or implantable cardioverter defibrillator (ICD)
• Requirement for oral or IV antibiotics that are not part of the subject's usual course of treatment within the past 14 days prior to screening

Trial design

Primary purpose: Device Feasibility

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Monarch device settings assessment group

Experimental group

Description:

Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study. The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures.

Treatment:

Device: Monarch Airway Clearance System